Please assess the completion status of the following clinical trial:

Trial Title: A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent;~* Age of 18 or above;~* Histology confirmed locally advanced unresectable or metastatic triple-negative breaset cancer;~* (KN046 monotherapy) failed at least one prior anthracycline and taxane containing systemic treatment, (KN046 plus nab-paclitaxel) systemic treatment naive;~* Measurable disease at baseline;~* ECOG 0-1;~* Adequate organ functions.~Exclusion Criteria:~* Untreated active CNS metastasis or leptomeningeal metastasis;~* Subjects receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs before initiation of trial treatment;~* Has interstitial lung disease, or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management;~* Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent; History of uncontrolled intercurrent illness; Known severe hypersensitivity reactions to antibody drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KN046 (Type: EXPERIMENTAL): Subjects will receive KN046 at a dose of 3 mg/kg or 5 mg/kg via intravenous infusion on Days 1 and 15 of every 28-day cycle until disease progression, unacceptable toxicity or completion of 2 years of treatment
- KN046 plus nab-paclitaxel (Type: EXPERIMENTAL): Subjects will receive KN046 at a dose of 3 mg/kg or 5 mg/kg via intravenous infusion on Days 1 and 15 of every 28-day cycle until disease progression, unacceptable toxicity or completion of 2 years of treatment Subjects will receive nab-paclitaxel at a dose of 100 mg/m2 via intravenous infusion on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity

Based on this trial design, predict the completion outcome and termination type (if applicable).